ESPE2023 Poster Category 1 Multisystem Endocrine Disorders (28 abstracts)
Childhood cancer survivors endocrine late effects: one year retrospective observational study
Eleni P Kotanidou 1 , Vasiliki Rengina Tsinopoulou 1 , Styliani Giza 1 , Eleni I Sakellari 1 , Stergianna Douma 1 , Vasiliki Antari 2 , Maria Palampougiouki 2 , Maria Ioannidou 2 , Athanasios Tragiannidis 2 , Emmanouil Hatzipantelis 2 & Assimina Galli-Tsinopoulou 1
1Unit of Pediatric Endocrinology and Metabolism, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece. 2Unit of Pediatric Oncology-Hematology, 2nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
Objectives: Childhood cancer survivors (CCS) are a growing population group. Current oncology treatments have led to improved patient survival rates and an increase in late effects of treatment. Endocrine disturbances, such as pituitary insufficiency, thyroid dysfunction and obesity are the most common late endocrine effects of oncology treatments. The purpose of the study was to investigate the endocrine health of CCS and to record the prevalence of late endocrine effects.
Methods: Over a period of 12 months (3/2022-3/2023), sixty CCS (32 boys), aged 10.92±4.7 years, were studied. Patients were followed-up every 3-6 months after the first endocrinological assessment.
Results: The CCS had presented with: 56.8% hematologic malignancy (46.7% acute lymphoblastic leukemia, 5% acute myeloid leukemia, 1.7% chronic myeloid leukemia, 1.7% myelodysplastic syndrome, 1.7% chronic congenital neutropenia), 18.3% solid tumors of central nervous system (3.3% pituitary germinoma, 3.3% brain glioma, 8.3% medulloblastoma, 1.7% neuroblastoma, 1.7% squamous cell carcinoma) and 24.9% other tumor (11.7% lymphoma, 3.4% ovarian germinoma, 1.7% rhabdomyosarcoma, 1.7% Ewing sarcoma, 1.7% hepatoblastoma, 1.7% Langerhanshistiocytosis, 1.7% intestinal carcinoma, 1.3% other). The mean age at diagnosis of malignancy was 7.07±4.68 years. All patients received chemotherapy, 35.0% received radiotherapy and 16.7% bone marrow transplantation while relapse occurred in 18.3%. Late endocrine effects were recorded as disturbances of: 35% thyroid, 10% pituitary, 8.3% puberty,1.7% adrenals, 18.3% glucose metabolism, 28.3% bone mass and 23.3% body weight.
Conclusion: The increased endocrine morbidity in CCS emphasizes the need for continued and thorough endocrinological follow-up of these patients as well as the importance of a structured transition to adult endocrinology care.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more